leadf
logo-loader
viewFSD Pharma
(
CSE:HUGENASDAQ:HUGE
)

FSD Pharma to buy pharma group Lucid Psycheceuticals in a stock deal worth US$9 million

FSD said the acquisition provided it with new assets at the forefront of new medicine and represented a 'paradigm shift' in its development

FSD Pharma -
Founded in 2020, Lucid is developing novel molecules and targeting some of the most challenging neurodegenerative diseases, such as MS, Alzheimer's and Parkinson's disease

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc is to buy Canada-based specialty psychedelic pharma group Lucid Psycheceuticals Inc in a stock deal worth around US$9 million (C$11.3 million). 

The life sciences holding company said the acquisition provided it with new assets at the forefront of new medicine and represented a 'paradigm shift' in its development.

Founded in 2020, Lucid is developing novel molecules and targeting some of the most challenging neurodegenerative diseases, such as Multiple Sclerosis (MS), Alzheimer's and Parkinson's disease.  It also has exclusive worldwide licensing rights from the University Health Network, North America’s largest health research organization, to a patent-protected family of new chemical entities (NCEs).

READ: FSD Pharma appoints Anthony Durkacz as its new interim chief executive officer

"Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies," said Anthony Durkacz, the interim CEO of FSD Pharma (CSE:HUGE, NASDAQ:HUGE).

Professor Lakshmi Kotra, co-founder and CEO of Lucid, added: "We started with a vision to accelerate therapies for Total Brain Health. Since inception, we have made significant progress and built a strong scientific and execution team. We are excited to enter a new phase of growth with FSD Pharma."

The deal is by way of a three-cornered amalgamation between Lucid, FSD Pharma and a wholly-owned subsidiary of FSD Pharma.

Around 4.5 million Class B subordinate voting shares in the capital of FSD Pharma will be issued as consideration with a deemed aggregate purchase price of around US$9 million.

The closing of the transaction is subject to customary closing conditions, including Lucid obtaining the requisite shareholder approval at a special meeting of Lucid shareholders, and the deal is expected to close this September.

FSD Pharma is a life sciences holding company building a portfolio of diversified therapeutic assets and innovative healthcare and biotech services.

Contact the writer at giles@proactiveinvestors.com

Quick facts: FSD Pharma

Follow
CSE:HUGE

Price: 1.95 CAD

Market Cap: $69.88 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

FSD Pharma 'excited' to acquire pharma group Lucid Psycheceuticals to...

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc (CSE:HUGE) (NASDAQ:HUGE) Interim CEO Anthony Durkacz tells Proactive the group is to buy Canada-based specialty psychedelic pharma group Lucid Psycheceuticals Inc in a stock deal worth around US$9 million (C$11.3 million). Durkacz says the life sciences...

4 weeks, 2 days ago

2 min read